MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Last trade$1.22
Day change+$0.21 (+20.79%)
Day range$0.987 – $1.25
Volume1,496,969
Market cap$62M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$62.37M
Price / earnings
—
Price / book
4.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.49×
Profitability
Earnings per share
-$0.41
Return on assets
-113.66%
Return on equity
-171.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.41×
Quick ratio
3.41×
Cash ratio
3.3×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MAIA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.69M
$2.68M
$3.42M
$2.44M
$3M
$2.06M
$2.23M
$2.04M
Research and development
$5.34M
$5.64M
$3.53M
$1.88M
$6.36M
$3.11M
$3.2M
$2.97M
Total operating expenses
$8.02M
$8.32M
$6.95M
$4.32M
$9.36M
$5.17M
$5.43M
$5M
Operating income
-$8.02M
-$8.32M
-$6.95M
-$4.32M
-$9.36M
-$5.17M
-$5.43M
-$5M
Interest expense
$186.19K
$0
$0
$0
$78.43K
$0
$0
-$57
Income before taxes
-$7.18M
-$7.94M
-$6.37M
-$3.63M
-$8.9M
-$5.35M
-$4.52M
-$3.57M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.18M
-$7.94M
-$6.37M
-$3.63M
-$8.9M
-$5.35M
-$4.52M
-$3.57M
Net income attributable to common shareholders
-$7.18M
-$7.94M
-$6.37M
-$3.63M
-$8.9M
-$5.35M
-$4.52M
-$3.57M
EBITDA
-$8.02M
-$8.32M
-$6.95M
-$4.32M
-$9.36M
-$5.17M
-$5.43M
-$5M
Basic earnings per share
-$0.12
-$0.13
-$0.14
-$0.10
-$0.27
-$0.18
-$0.16
-$0.14
Diluted earnings per share
-$0.12
-$0.13
-$0.14
-$0.10
-$0.27
-$0.18
-$0.16
-$0.14
Recent news
Company coverage with links to the original publishers.
MAIA Biotechnology completed a $30 million equity raise and announced 2026 strategic milestones including Phase 3 trial progress for its ateganosine cancer therapy. The company secured FDA Fast Track designation and reported positive Phase 2 data showing median PFS of 5.6 months and OS of 17.8 months. Diamond Equity Research maintains a $10.27 per share valuation based on successful execution of clinical programs.
MAIA Biotechnology, Inc. announced the successful closing of an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. The company plans to use net proceeds for clinical trials and general corporate purposes.
MAIA Biotechnology priced an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. Net proceeds will be used for clinical trials and general corporate purposes. The offering is expected to close on March 4, 2026.
MAIA Biotechnology announced an underwritten public offering of common stock and pre-funded warrants, with Konik Capital Partners LLC serving as sole book-running manager. The company intends to use net proceeds for clinical trials and general corporate purposes. MAIA's lead program, ateganosine (THIO), is a potential first-in-class cancer telomere targeting agent in clinical development for NSCLC treatment.
The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.